{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:31:17Z","timestamp":1781796677161,"version":"3.54.5"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Blinatumomab is a bispecific T-cell engager approved for the treatment of relapse\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL). Most studies evaluating blinatumomab were conducted in Caucasian populations, with limited data available in Chinese patients. This retrospective study aims to evaluate the efficacy and safety of blinatumomab in Chinese patients with R\/R B-ALL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 19 patients (10 males, 9 females) with a median age of 49 years (range: 9-66) who received blinatumomab treatment at the Aerospace Center Hospital between November 2021 and November 2024 were included. Rates of complete remission (CR) and minimal residual disease (MRD) response, 1-year overall survival (OS) and relapse-free survival (RFS), and adverse events were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median number of blinatumomab cycles administered was 1 (range: 1-6). Twelve (80.0%, 95% confidence interval [CI]: 51.9-95.7) of the 15 patients with overt marrow disease achieved CR, with 8 achieving MRD negativity. Four patients with &amp;lt; 5% blast but positive MRD all sustained CR and achieved MRD negativity. The overall MRD response rate was 63.2% (12\/19, 95%CI: 38.4-83.7). The 1-year overall survival (OS) and relapse-free survival (RFS) rates were 64.2% \u00b1 12.1% and 73.3% \u00b1 11.4%, respectively. MRD responders had significantly better OS compared to MRD non-responders (log-rank test, P = 0.023). Of the 16 patients with CR, 62.5% proceeded to allogeneic hematopoietic stem cell transplantation (allo-HSCT). The most frequent adverse event was cytokine release syndrome, which occurred in 11 patients (10 with grade 1\u20132 and 1 with grade 3 severity).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Blinatumomab is both effective and well-tolerated in Chinese patients with R\/R B-ALL, achieving high rates of CR and MRD negativity and facilitating more patients\u2019 eligibility for allo-HSCT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1587185","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:39:52Z","timestamp":1747028392000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of blinatumomab in Chinese patients with relapsed\/refractory B-cell acute lymphoblastic leukemia: a single-center retrospective study"],"prefix":"10.3389","volume":"15","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1038\/srep04227","article-title":"Survival improvement by decade of patients aged 0\u201314 years with acute lymphoblastic leukemia: a SEER analysis","volume":"4","author":"Ma","year":"2014","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"key":"B9","article-title":"Agents for refractory\/relapsed acute lymphocytic leukemia in adults","volume":"18","author":"Qian","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2017.05.015","article-title":"Hematopoietic cell transplantation for acute lymphoblastic leukemia in adult patients","volume":"10","author":"El Fakih","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"L\u00f6ffler","year":"2003","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-852376","article-title":"Taking a \u201cBiTE out of ALL\u201d: blinatumomab approval for MRD-positive ALL","volume":"133","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.09.001","article-title":"Chinese guidelines for diagnosis and treatment of adult acute lymphoblastic leukemia (2021)","volume":"42","year":"2012","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3760\/cma.j.issn.0253-2727.2022.10.001","article-title":"Chinese expert consensus of allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia (2022)","volume":"43","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1396890","article-title":"Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia","volume":"10","author":"Ribera","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/BLCTT.S223894","article-title":"Evaluating blinatumomab for the treatment of relapsed\/refractory ALL: design, development, and place in therapy","volume":"10","author":"Sigmund","year":"2020","journal-title":"Blood Lymphat Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v100:6","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.v115:1","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/cancers14020426","article-title":"Blinatumomab in Children and Adolescents with Relapsed\/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers","volume":"14","author":"Beneduce","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05725-9","article-title":"Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study","volume":"103","author":"Leotta","year":"2024","journal-title":"Ann Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2111992","article-title":"Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study","volume":"27","author":"Zhou","year":"2022","journal-title":"Hematology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10637-024-01435-1","article-title":"Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia","volume":"42","author":"Zhou","year":"2024","journal-title":"Invest New Drugs"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia","volume":"44","author":"Shi","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03854-0","article-title":"Safety and efficacy of blinatumomab: a real world data","volume":"99","author":"Apel","year":"2020","journal-title":"Ann Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: A meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005579","article-title":"Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis","volume":"6","author":"Locatelli","year":"2022","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-020-00342-x","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study","volume":"10","author":"Locatelli","year":"2020","journal-title":"Blood Cancer J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","article-title":"Survival after blinatumomab treatment in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Gore","year":"2018","journal-title":"Blood Cancer J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v125.23","article-title":"Transplantation in adults with relapsed\/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1587185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:39:54Z","timestamp":1747028394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1587185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":43,"alternative-id":["10.3389\/fonc.2025.1587185"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1587185","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"article-number":"1587185"}}